

EHSF 2026

From Gene to Clinic in HS



15th CONFERENCE OF THE EUROPEAN HIDRADENITIS SUPPURATIVA FOUNDATION

Malta | Feb 4-6, 2026

DETAILED SCIENTIFIC PROGRAMME

DETAILED SCIENTIFIC PROGRAMME

Start	end/session n shortcut	Session title	Room
Wednesday, February 4			
08:30	11:00	Individual Poster Viewing	Foyer
10:00	11:00	GHISA: Global Hidradenitis Suppurativa Atlas	Grand Master Suite
Chair: Gregor Jemec			
10:30	11:15	Coffee break	
11:00	12:00	GHISA Aftertalk	Pinto
11:00	12:00	Basic Research incl. Genetics/Pathophysiology - part 1	Grand Master Suite
Chairs: Kelsey van Straalen, Axel Villani, Robert Sabat			
11:00		Overview	
11:10	S-01-01	Single-cell spatial profiling identifies a mucosal-like epithelial signature in hidradenitis suppurativa tunnels (#153) <u>Qing-Sheng Mi</u> , Peter Dimitrion, Jesse Veenstra, Ping Wang, Jeff Cruz, Iltefat Hamzavi, Indra Adrianto, Li L. Zhou	
11:20	S-01-02	Lesional hidradenitis suppurativa <i>ex vivo</i> model shows Bimekizumab's modulation of IL-17 and IL-1 pathways across lesional subtypes, aligning with clinical efficacy <u>Alizée Le Riche</u> , Prama Pallavi, Ilaria Piccini, Falk G. Bechara, Janin Edelkamp, <u>Marta Bertolini</u> This study is a collaboration of QIMA Life Sciences, QIMA Monasterium GmbH, Münster, Germany and Mirador Therapeutics, Inc., San Diego, USA.	
11:30	S-01-03	3D Seboskin model of hidradenitis suppurativa: Insights into antibiotic response <u>Georgia Vradeli</u> , Christos C. Zouboulis	
11:40	S-01-04	Using the hidradenitis suppurativa diseased skin organ culture model to assess mechanisms of action and efficacy in disease amelioration of FDA-approved drugs <u>Joana Viola-Söhnlein</u> , Markus Fehrholz, Edwige Nicodeme, Falk Bechara, Sylke Schneider-Burrus, Valerie Julia, Karin Pappelbaum, <u>Marta Bertolini</u> , Janin Edelkamp	
11:50	S-01-05	Murine model reveals interplay between skin microbiome triggered neuroinflammation and depression in hidradenitis suppurativa <u>Eleonore Beurel</u> , Sujad Younis, Ariane R. Kalifa, Tammy Gonzalez, Hadar Lev-Tov, Natasa Strbos, <u>Irena Pastar</u>	
12:30	13:30	Nurses' Session	Pinto
Chairs: Maria Solera, Shani Fisher			
12:30	13:30	Industry Lunch Symposium	Grand Master Suite
12:30	13:30	Lunch break	
13:30	15:00	Basic Research incl. Genetics/Pathophysiology - part 2	Grand Master Suite
Chairs: Francesca Prignano, Lynn Pethukova, Sophie Hüe			
13:30		Overview	
13:40	S-02-01	Single cell and spatial transcriptomics profiling of lesional hidradenitis suppurativa skin provides insight into disease pathogenesis <u>Bo Bang</u> , Axel Villani, John Frew, Aashil Batavia, Sandro Bruno, Celine Cojean, Bruno Cenni, Ben Roediger, Lukas Roth, James Krueger, Johann E. Gudjonsson	

13:50	S-02-02	GJB3 variants disrupt gap junction function and epithelial barrier in familial hidradenitis suppurativa, suggesting a novel etiological mechanism <u>Elena Maria Nardacchione</u> , Sara Roncarà, Chiara Moltrasio, Ronald Rodrigues Moura, Blendi Ura, Eduardo Sommella, Blendi Ura, Nour Balasan, Barbara Vergani, Giorgia Cardinali, Daniela Kovacs, Hassan Riad, Angelo Valerio Marzano, Sergio Crovella, Paola Maura Tricarico	
14:00	S-02-03	Spatial Mapping of Autoimmune Pathogenesis in Hidradenitis Suppurativa Using Transcriptomics and High-resolution Multiplexed Imaging <u>Catherine Lu</u>	
14:10	S-02-04	Proteomic analysis of the Phase 2 MIRA trial population highlights IL-17 signaling and draining tunnel lesions as pivotal to systemic inflammation in hidradenitis suppurativa Kristian Reich, <u>Eva Cullen</u> , Sara Pereira, Conor M. Smith, Alex Godwood, Anthea Newton, Jean M. Fletcher, Brian Kirby, Marta Bertolini, Alexa B. Kimball, James G. Krueger	
14:20	S-02-05	Involvement of epidermal cell-cell junctions and desmosomal organization in the pathogenesis of syndromic hidradenitis suppurativa Chiara Moltrasio, Paola M. Tricarico, Cecilia Del Vecchio, Elena M. Nardacchione, Ronald Moura, Sara Roncarà, Francesca Satolli, Flavia Manzo Margiotta, Valentina Dini, Angelo V. Marzano, <u>Sergio Crovella</u>	
14:30	S-02-06	Changes of neutrophil extracellular traps (nets) blood levels to surrogate response to treatment in hidradenitis suppurativa Angeliki Vlysidou, Styliani Theohari, Anastasia Kourtesa, Theodora Kanni, Pavlina Mesiri, Konstantinos Leventogiannis, <u>Evangelos Giamarellos-Bourboulis</u>	
14:40	S-02-07	Proteomic Profiling of Hidradenitis Suppurativa Skin Reveals Distinct Inflammatory Signatures Compared to Perilesional and Healthy Control Skin (#130) <u>Jorge Romani</u> , Mar Luque, Francois Brillet, Javier Fernández-Vela, Maria Jose Fabrega, Lorena Toloza, Carlos Muñoz-Santos, Maria Polz, Marc Güell, Antonio Guilabert	
14:50	S-02-02	Black market GLP-1 receptor agonist use in hidradenitis suppurativa Rachel Drayne , Brian Kirby, Rosalind Hughes	
15:00	16:00	Coffee break	
15:00	15:45	Guided poster walk	Foyer
15:00	16:00	Key Concepts and Live Demo on US of HS Chair: Ximena Wortsmann, Marco Romanelli, Eva Vilarrasa	Grand Master Suite
16:00	17:45	Ultrasound Imaging Workshop Chair: Ximena Wortsmann, Marco Romanelli, Alejandro Molina-Leyva	
17:00	18:00	Guided poster walk	Foyer
18:00	18:45	Opening Ceremony and Keynote Chairs: Christos Z.Zouboulis, Michael Boffa, Prof Godfrey Laferla Keynote: Brendon Scicluna. 1. Prof Dr Christos C. Zouboulis (EHSF President) 2. Dr Michael Boffa (Conference President) 3. Prof Godfrey Laferla (Dean of Faculty of Medicine & Surgery, University of Malta) Keynote Lecture Dr Brendon Scicluna: "Rethinking Inflammation in the Era of Immune Archetypes"	Grand Master Suite
18:45	20:30	Get Together in the Exhibition	Exhibition

Thursday, February 5

08:00	09:00	EHSF General Assembly	Grand Master Suite
09:00	10:15	Evidence-Based Decision Making/Guidelines (part 1)	Grand Master Suite
Chairs: Thrasylvoulos Tzellos, Lukasz Matusiak, Branka Marinovic			
09:00		Overview	
09:15	S-03-01	A Roadmap For Research And Disease Management In Hidradenitis Suppurativa To Improve Patient Outcomes Noor F. Goandal , Bibi Petersen, Annett Finken, Gregor B. Jemec In collaboration with the HS:SMILES Stakeholders: Aikaterini I. Liakou, Afsaneh Alavi, Anders Christensen, Ann Leland, Angelo Valerio Marzano, Athena Mammis-Gierbolini, Barry McGrath, Benita Mayaki, Bente Villumsen, Karsten R. Moeller, Christopher Sayed, Chua Xue Jing, Daniel B. Eisen, Daudi Mavura, Ditte M. Saunte, Ehiage Anaba, Errol P. Prens, Farida Benhadou, Francesca Prignano, Yousef Bin Amer, Shannon Piche, Hessel H. Van der Zee, Jacek C. Szepietowski, John Ingram, Lise Beier, Kelsey R. van Straalen, Lauren Orenstein, Lukasz Matusiak, Maria Cecilia Rivitti-Machado, Mohammed Saiful Islam Bhuiyan, Haley Naik, Nisha Chandran, Philippe Guillem, Raed Alhusayen, Robert Micheletti, Stine Hallgren, Susanne de Goeij, Thrasylvoulos Tzellos, Vincenzo Bettoli	
09:25	S-03-02	HSPlus: an Integrated Practice Unit for Hidradenitis Suppurativa Leen Vermoesen , Elfie Deprez, Emma Vyvey, Rani Soenen, Julie Depelseneer, Bernard Kint, Jo Lambert	
09:35	S-03-03	Disease Burden and Management of Hidradenitis Suppurativa From the Perspectives of Patients and Physicians in Europe: Findings From the Global HERALD (Hidradenitis Suppurativa Experiences in the Real World) Survey (#215) John R. Ingram , Hannah E. Wainman, Eva Vilarrasa, Alejandro Molina-Leyva, Matthias Augustin, Jean-Luc Perrot, Joslyn S. Kirby, Theresa Amoloja, Leandro L. Santos, Haobo Ren, Joseph Cordaro, Angelo Valerio Marzano	
09:45	S-03-04	Referral patterns among healthcare professionals in the diagnosis and management of patients with hidradenitis suppurativa in Germany: Week 24 results from the HELyx implementation science study Falk G. Bechara , Antonio Martorell, Pierre-André Becherel, John R. Ingram, Georgios Kokolakis, Barry M. McGrath, Yvonne Geissbühler, Elena Hillmann, Mirjam Fliesser, Mahrukh Zahid, Michael Fritz, Chaitali B. Pisal, Nicola Barnes, Rachel Davis, Abigail Herbst, Hannah E. Kling, Marco Romanelli	
09:55	S-03-05	Risk calculator for disease progression in patients with moderate hidradenitis suppurativa: A call to action Albert Martin-Poch, Carmen Garcia-Moronta, Javier Leon-Perez, Julia Castro-Martin, Andrea Rodriguez-Sanna, Alberto Soto-Moreno, Eva Vilarrasa, Alejandro Molina-Leyva	
10:05	S-03-06	The disease burden and unmet treatment need of patients with hidradenitis suppurativa in Denmark and Norway: Real-world data from the HISREG registry Øystein Grimstad , Ana F. Macedo, Thrasylvoulos Tzellos , Ditte Marie L. Saunte, Inger Marie Skoie, Ingrid Snekvik, Tanja Tran, Johan L. Hansen, Aijing Shang, Gregor B. Jemec, Anne-Marte Henriksen	
10:15	10:45	Coffee break	
10:15	10:45	Guided poster walk	Foyer

10:45	12:00	Epidemiology/Clinical Phenotypes	Grand Master Suite
		Chairs: Ditte M.L. Saunte, Hessel H. van der Zee, Lawrence Scerri	
10:45		Overview	
11:00	S-04-01	Multidimensional Phenotypic Mapping of Hidradenitis Suppurativa: A Tertiary Care Center Experience <u>Samed Şahin</u> , Yusuf Can Edek, Sezai Leventoğlu, Tarkan Karakan, Esra Adışen	
11:10	S-04-02	Assessing socioeconomic inequality in hidradenitis suppurativa: Insights from an Irish cohort <u>Emma Carroll</u> , Rachel Drayne, Maria A. Visan, Emily Pender, Carl Orr, Rosalind Hughes, Brian Kirby	
11:20	S-04-03	Who are the non-progressors? Description of patients with longstanding, mild hidradenitis suppurativa <u>Elif Sali</u> , Daan P. de Kort, Anais L. van Haaren, Kelsey van Straalen, Hessel van der Zee	
11:30	S-04-04	Streptococcus anginosus as a Trigger of Systemic Inflammatory Response in Hidradenitis Suppurativa: Clinical Correlations <u>João Paulo Turri Brufatto</u> , Luciana Vilela Gomide, Ariany Tomaz de Aquino Saran Denofre, Juliana Yumi Massuda Serrano, <u>Renata F. Magalhães</u>	
12:00	12:30	Keynote Lecture	Grand Master Suite
		Nikolai Pace, Micahel J. Boffa Prof. Nikolai Pace: "From Genetic Susceptibility to Clinical Reality: Charting the Course for HS"	
12:45	13:45	Industry Lunch Symposium	Grand Master Suite
12:45	13:45	Patient Organizations representatives Meeting	Pinto
12:45	13:45	Lunch break	
14:15	14:45	Guided poster walk	Foyer
14:45	16:00	Surgical Treatment	Grand Master Suite
		Chairs: Philippe Guillem, Falk Bechara, Duncan Aquilina	
14:45		Overview	
15:00	S-05-01	Investigating the efficacy and safety of surgical techniques in hidradenitis suppurativa: A Systematic Review and Meta-analysis <u>Koorosh Karimi</u> , Katalin Martyn, Fanni A. Meznerics, Karen Fazekas, Nada Elseify, Arian Rowshanshad, Bella A. Kelemen, Norbert Kiss, Peter Hegyi, Kende K. Lőrincz, András Bánvölgyi	
15:10	S-05-02	Optimising surgical care pathways in Hidradenitis Suppurativa: a retrospective audit of dermatology–plastic surgery collaboration in Malta <u>Leonie Mifsud</u> , Luca A. Borg, Dillon Mintoff, Michael J. Boffa	
15:20	S-05-03	Impact of secukinumab on surgical outcomes in Hidradenitis Suppurativa: A Retrospective Cohort Analysis <u>Pablo Torres Salomón</u> , <u>Pedro J. Navarro Guillamón</u> , Elia Boza Villar, Marisol Contreras Steyls, Jorge A. Suárez Pérez, Enrique Herrera Acosta	
15:30	S-05-04	Clinical outcomes after radical excision with ‘star-like’ wound closure in hidradenitis suppurativa: a retrospective cohort from a Chilean center <u>Valentina Burckhardt</u> , Catalina Barros, Javier Fernández, Daniela Saavedra	
15:40	S-05-05	SMASH study: evaluation of Surgical MARGins after excision of Hidradenitis Suppurativa lesions <u>Christelle Enault</u> , Virginie Vlaeminck-Guillem, Axel P. Villani, <u>Philippe Guillem</u>	
15:50	S-05-06	Ultrasound-guided 70 MHz deroofing in Hidradenitis Suppurativa: healing by secondary intention and clinical outcomes <u>Alessandra Michelucci</u> , Giammarco Granieri, Flavia Manzo Margiotta, Bianca Cei, Marco Romanelli, Valentina Dini	

16:00	16:45	Coffee break	
16:15	16:45	Guided poster walk	Foyer
16:45	17:45	Emerging Treatments (part 1)	Grand Master Suite
Chairs: Errol P. Prens, Veronique del Marmol, Sue Aquilina			
16:45		Overview	
17:00	S-06-01	A Phase 2 Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Lutikizumab in Biologic-Naïve Adult Patients With Moderate-To-Severe Hidradenitis Suppurativa Alexa B. Kimball, Hermenio Lima, Susan Poelman, Antonio Martorell, John Frew, Konrad T. Sawicki, Amy Gamelli, Leonidas Drogaris, Yu Han, Mona Akbari, David Williams, Falk G. Bechara	
17:10	S-06-02	Safety, pharmacokinetics, pharmacodynamics and clinical improvement with LAD191, a monoclonal antibody targeting IL-1RAP, in adults with hidradenitis suppurativa from Part 3 of a Phase 1 study Jorge L. Diaz, Amit B. Bhavsar , Hilary Siddall , Xavier Garcia Sala, Ana M. Perez Fierro, Marta Calbet Murtro, Lucio Malvisi, Esther Garcia Gil	
17:20	S-06-03	Maintenance and Deepening of Clinical Response in Adult Patients With Moderate-to-Severe Hidradenitis Suppurativa Receiving Upadacitinib: Post Hoc Analysis of a Phase 2 Study Ziad Reguiaï, Evangelos Giamarellos-Bourboulis, Pedro Mendes-Bastos, Amit Garg, Maria C. Rivitti-Machado, Tianyu Zhan, Xiaohong Huang, Beth Rycroft, Bethanee J. Schlosser, Monika Arenbergerová	
17:30	S-06-04	Decoding the IL-17 axis in hidradenitis suppurativa: Pharmacodynamic profiling of the Nanobody[®] sonelokimab reveals IL-19 and PI3 as biomarkers of IL-17 pathway activity Kristian Reich, Eva Cullen , Sara Pereira, Conor M. Smith, Alex Godwood, Anthea Newton, Jean M. Fletcher, Brian Kirby, Alexa B. Kimball, James G. Krueger	
17:40	S-06-05	Skin Pain and Itch Improvements With Povorcitinib: STOP-HS1/STOP-HS2 Interim Week 24 Pooled Results John W. Frew , Veronique del Marmol, Hans Christian Ring, Antonio Martorell, Ziad Reguiaï, Angelo Valerio Marzano, Hessel H. van der Zee, Hadar Lev-Tov, Jennifer L. Hsiao, Jacek C. Szepletowski, Huiling Zhen, Leandro L. Santos, Joslyn S. Kirby, Martina L. Porter	
Friday, February 6			
08:00	09:30	Evidence-Based Decision Making/Guidelines (Part 2)	Grand Master Suite
Chairs: Errol P. Prens, Antonio Martorell, Dillon Mintoff			
08:00		Overview	
08:15	S-07-02	Delphi Consensus Criteria for Early Biologic Therapy in Hidradenitis Suppurativa: Results from the 14th European HS Foundation Conference Georgios Nikolakis , Erkan Alpsoy, Florian Anzengruber, Matthias Augustin, Falk G. Bechara, Pierre-André Becherel, Farida Benhadou, Vincenzo Bettoli, Joana Cabete, Raffaele Dante Caposiena Caro, Antonella Di Cesare, Giovanni Damiani, Valentina Dini, Evangelos J. Giamarellos-Bourboulis, Krisztián Gáspár, Katalin Glasenhardt, Philippe Guillem, Ariela Hafner, Barbara Horvath, John Ingram, Vaiva Jarienè, Gregor B. Jemec, Alexander Katoulis, Natalia Kirsten, Georgios Kokolakis, Piotr K. Krajewski, Aikaterini I. Liakou, Flavia Manzo Margiotta, Angelo V. Marzano, Antonio Martorell, Lukasz Matusiak, Dillon Mintoff, Alejandro Molina Leyva, Andreas Pinter, Anna Pirogova, Maurizio Podda, Francesca Prignano, Jorge Romani, Marco Romanelli, Elia Rosi, Samed Sahin, Ditte M. Saunte, Sylke Schneider-Burrus, Mariano Suppa, Jacek Szepletowski, Andrea Szegedi, Simon Francis Thomsen, Thrasylvoulos Tzello, Anastasia Trigoni, Hessel van der Zee, Kelsey van Straalen, Skaidra Valiukevičienė, Eva Vilarrasa, Esther von Stebut, Christos C. Zouboulis	
08:25	S-07-03	Identifying High-Risk Hidradenitis Suppurativa Patients for Spondyloarthritis: Diagnostic Accuracy of the Early Sacroiliitis Screening Tool (ESHST) Umut Bakay, Ozge Karstarlı , Tuğba İzci Duran, Niyazi Cetin Umut Bakay: Study design, data collection, manuscript writing. . Ozge Karstarlı: Dermatologic evaluation, manuscript writing,manuscript revision. Tuğba İzci Duran: Patient recruitment, manuscript writing Niyazi Cetin: Patient recruitment manuscript writing	
08:35	S-07-04	Development of a hidradenitis suppurative damage scale: a delphi consensus study Sherry Ershadi , John S. Barbieri, Noah Goldfarb, Martin Okun	

08:45	S-07-05	Early vs Delayed Initiation of Adalimumab in Hidradenitis Suppurativa: A Cost-Effectiveness Analysis <u>Joshua A. Kent</u> , Gabriel Santos Malave, Sabrina Hundal, Julian Cappelli, Elena Netchiporouk, Stephanie Goldberg, Larisa J. Geskin	
08:55	S-07-06	Risk of hidradenitis suppurativa in children and adolescent patients with juvenile arthritis: a population-based prospective cohort study <u>Nadja H. Pedersen</u> , Valdemar W. Nielsen, Jacob P. Thyssen, Alexander Egeberg, Simon F. Thomsen, Nikolaj Holgersen	
09:05	S-07-07	Eligibility in clinical trials vs. real-life biologic eligibility in patients with hidradenitis suppurativa: the importance of new treatment guidelines and ultrasonographic assessment of tunnels <u>Francisco J. Leon-Perez</u> , Carmen García-Moronta, Carmen Mochón-Jimenez, Alexandra Alturo-Pons, Alberto Soto-Moreno, Eva Vilarrasa, <u>Alejandro Molina-Leyva</u>	
09:30	10:15	Guided poster walk	Foyer
09:30	10:15	Coffee break	
10:15	11:15	Imaging/AI/Social Media Chairs: Ximena Wortsman, Jorge Romani	Grand Master Suite
10:15		Overview Prof. Ximena Wortsman (1. Chair) Titel: "New Trends and Advances of Ultrasound in Hidradenitis Suppurativa"	
10:30	S-08-01	Introducing an artificial intelligence-based tool for predicting disease progression and risk Stratification in Hidradenitis Suppurativa <u>Antonio Martorell</u> , Alfonso Medela, Andy Aguilar, Gerardo Fernández Moreno, Taig Mac Carthy ² , Victor Gisbert Climent	
10:40	S-08-02	Ultra-High-Frequency Ultrasound (UHFUS) monitoring of dermal microtunnel remodeling in Hidradenitis Suppurativa: a 12-Week prospective study <u>Alessandra Michelucci</u> , Bianca Cei, Giammarco Granieri, Flavia Manzo Margiotta, Marco Romanelli, <u>Valentina Dini</u>	
10:50	S-08-03	Integrating Thermography and Ultra High-Frequency Ultrasound for Disease Assessment in Hidradenitis Suppurativa <u>Flavia Manzo Margiotta</u> , Eleni Kourtellari, Alessandra Michelucci, Marco Romanelli, Valentina Dini, Christos C Zouboulis	
11:00	S-08-04	Do only draining tunnels matter? Ultrasound and histologic evidence that non-draining tunnels contribute to disease burden in Hidradenitis Suppurativa Alexandra Alturo, Laura Mateu-Arrom, Javier León, Carmen Monchón, Alberto Soto, Alejandro Molina-Leyva, <u>Eva Vilarrasa</u>	
11:15	12:15	Quality of Life/Mental Health/Psychodermatology Chairs: Michael J. Boffa, Ruta Ganceviciene	Grand Master Suite
11:15		Overview	
11:30	S-09-01	Living with Hidradenitis Suppurativa in France: diagnosis, burden and care expectations from the ECHOS patient-led study <u>Philippe Guillem</u> , Daniela R. Castro, Carole Gautier, Marie-France Bru, Manon Molins, Mathilde Chavaette, Anne Duburcq, Karyn le Goff, Marion Moulin, Laurent Abramowitz On behalf of UCB-Collaboration	
11:40	S-09-02	A Pilot Study Characterizing the Economic Burden of Living with Hidradenitis Suppurativa <u>Kelly Frasier</u> , Natalie Ingraham, Alexander Velaoras, Alex Silberzweig, Andrew Strunk, <u>Amit Garg</u>	

11:50	S-09-03	Hidradenitis Suppurativa Quality of Life (HiSQOL®) Questionnaire: Data from 1.188 patients from the Spanish Hidradenitis Suppurativa Registry of the Spanish Academy of Dermatology and Venereology (REHS)	
		<u>José C. Pascual</u> , Juan G. Garcías-Ladaria, Juli Bassas, Lucía Carnero, Eva Vilarrasa, Emil Masferrer, Raquel Rivera, Marta Ruano, Laura Salgado-Boquete, Alejandro Molina-Leyva, Marta Mendieta, Enrique Herrera, Rafael Botella, Antonio Martorell, Gemma Martín-Ezquerro, Hector Parandones, Patricia Garbayo, Irene Fuertes, Rafael Aguayo, Nuria No Pérez, María Isabel Rodríguez-Blanco, Yolanda Delgado, Laura M. Pericet, Mercè Grau-Pérez	
12:00	S-09-05	Patients' quality of life with hidradenitis suppurativa in Malta	
		<u>Stephanie Farrugia</u> , Dillon Mintoff, Michael J. Boffa	
12:10	S-09-04	Psychiatric comorbidity in hidradenitis suppurativa: a large-scale retrospective cohort study	
		<u>Piotr K. Krajewski</u> , Jacek C. Szepietowski	
12:20	12:50	Keynote Lecture	Grand Master Suite
		Haley Naik, Christos C. Zouboulis, Thrasyvoulos Tzellos	
12:50	13:50	Industry Lunch Symposium	Grand Master Suite
12:45	13:45	Lunch break	
14:00	15:15	Emerging Treatments (part 2)	Grand Master Suite
		Chairs: Brian Kirby, Afsaneh Alavi, Daniel Micallef	
14:00		Overview	
14:15	S-10-01	Real-World Experience with GLP-1/GIP Analogs in Hidradenitis Suppurativa: Emerging Therapeutic Insights	
		<u>Laura Mateu-Arrom</u> , Jose M. De Castro Garrido, Lluís Puig, Eva Vilarrasa	
14:25	S-10-02	Interim 24-Week IHS4 Outcomes With Povorcitinib in HS: Pooled Analysis From STOP-HS1 and STOP-HS2 Trials	
		<u>Christos C. Zouboulis</u> , Veronique del Marmol, Hans Christian Ring, Antonio Martorell, Ziad Reguiaï, Angelo Valerio Marzano, Hessel H. van der Zee, Jacek C. Szepietowski, Christopher J. Sayed, John W. Frew, Huiling Zhen, Leandro L. Santos, Joslyn S. Kirby, Martina L. Porter	
14:35	S-10-03	Characterization of the IHS4 Response to Lutikizumab Treatment in Patients With Moderate-to-Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy	
		<u>Falk G. Bechara</u> , Evangelos J. Giamarellos-Bourboulis, <u>Thrasyvoulos Tzellos</u> , Marni Wiseman, Eva Vilarrasa, Konrad T. Sawicki, Amy Gamelli, Yu Han, David A. Williams, Ruoyu He, Mona Akbari, Alexa B. Kimball	
14:45	S-10-04	Sonelokimab in moderate-to-severe HS: Topline efficacy and safety results from the Phase 3 VELA-1 and VELA-2 trials	
		<u>Brian Kirby</u> , Jacek C. Szepietowski, Melinda J. Gooderham, Kenneth B. Gordon, Alice B. Gottlieb, Iltefat H. Hamzavi, Jennifer L. Hsiao, James G. Krueger, Hadar Lev-Tov, Jack C. O'Brien, So Yeon Paek, Christopher J. Sayed, Vivian Y. Shi, Hessel H. van der Zee, Naomi Attar, Nancy Carpenter, Rajiv Sharma, Nuala Brennan, Alex Godwood, Eva Cullen, Kristian Reich, Martina L. Porter, <u>Alexa B. Kimball</u>	
14:55	S-10-05	Remibrutinib in patients with moderate to severe hidradenitis suppurativa: International Hidradenitis Suppurativa Severity Scoring System (IHS4) outcomes from a randomised, phase 2, double-blind, placebo-controlled, platform study	
		<u>Falk G. Bechara</u> , Errol P. Prens, Johann E. Gudjonsson, Bo Bang, Swati Ghanshani, Christian Loesche, Alexa B. Kimball	
15:05	S-10-06	Semaglutide for weight loss in obese patients with hidradenitis suppurativa and its impact on disease control and quality of life	
		<u>Rachel Drayne</u> , Daniel Lyons, Brian Kirby, Rosalind Hughes	
15:15	15:30	Coffee break	

15:30	16:45	Medical Treatment	Grand Master Suite
Chairs: Angelo V. Marzano, Axel Villani			
15:30		Overview	
15:45	S-11-01	<p>Impact of continuous secukinumab treatment on flare rates over 4 years in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials</p> <p><u>Georgios Kokolakis</u>, Pedro Mendes-Bastos, Martina Porter, Ziad Reguijai, Bertrand Paguet, Vipin Nair, Valeria Jordan M, Antonio Martorell</p>	
15:55	S-11-02	<p>Bimekizumab impact on dichotomous IHS4 response levels over 3 years in moderate to severe HS: Results from BE HEARD EXT</p> <p><u>Thrasylvoulos Tzellos</u>, Dillon Mintoff, Kelsey R. van Straaten, Angelo V. Marzano, Koremasa Hayama, Vivian Y. Shi, Evelina van Ree, Bengt Hoepken, Nicola Tilt, Christopher J. Sayed</p>	
16:05	S-11-03	<p>Adalimumab treatment patterns in adolescents with hidradenitis suppurativa</p> <p><u>Valdemar Wendelboe Nielsen</u>, Toluwani Taiwo, Sarah Coates., Haley B. Naik</p>	
16:15	S-11-04	<p>Pre-treatment markers of B cell activation predict response to adalimumab and rifampicin/clindamycin in patients with moderate to severe hidradenitis suppurativa</p> <p><u>Emily Pender</u>, Conor M. Smith, Emma Carroll, Rosalind Hughes, Brian Kirby</p>	
16:25	S-11-05	<p>The efficacy of continuous secukinumab treatment over 4 years, as measured by the International Hidradenitis Suppurativa Severity Scoring System (IHS4), in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials</p> <p><u>Christos Zouboulis</u>, Afsaneh Alavi, Athanassios Kyrgidis, Angelo Marzano, Thrasylvoulos Tzellos, Hessel van der Zee, Vipin Nair, Valeria Jordan, Bertrand Paguet, Antonio Martorell</p>	
16:35	S-11-06	<p>Role of Bimekizumab in Active Tunnels: A Retrospective Ultrasound Analysis of 22 Hidradenitis Suppurativa Cases</p> <p><u>Antonio Martorell</u>, Gemma Ochando-Ibernón, Virginia Sanz-Motilva, Marta Moya, Maria Solera-Talamante, Alberto Alfaro-Rubio</p>	
16:45	17:15	Awards & Closure	Grand Master Suite
Chairs: Christos C. Zouboulis, Vincenzo Bettoli			